Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Aytu Biopharma (AYTU) over the last 7 years, with Q4 2025 value amounting to $29000.0.

  • Aytu Biopharma's Amortization of Deferred Charges rose 357.14% to $29000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $111000.0, marking a year-over-year decrease of 6828.57%. This contributed to the annual value of $108000.0 for FY2025, which is 8190.95% down from last year.
  • As of Q4 2025, Aytu Biopharma's Amortization of Deferred Charges stood at $29000.0, which was up 357.14% from $29000.0 recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Amortization of Deferred Charges peaked at $170000.0 during Q4 2022, and registered a low of -$165000.0 during Q4 2021.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $63500.0 (2023), whereas its average is $53100.0.
  • Per our database at Business Quant, Aytu Biopharma's Amortization of Deferred Charges crashed by 45106.38% in 2021 and then soared by 68823.53% in 2022.
  • Over the past 5 years, Aytu Biopharma's Amortization of Deferred Charges (Quarter) stood at -$165000.0 in 2021, then soared by 203.03% to $170000.0 in 2022, then dropped by 9.41% to $154000.0 in 2023, then crashed by 81.82% to $28000.0 in 2024, then rose by 3.57% to $29000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $29000.0 for Q4 2025, versus $29000.0 for Q3 2025 and $26000.0 for Q2 2025.